With increasing age, the general population is increasingly vulnerable to the development of cerebral amyloid-β (Aβ) plaque and neuronal phospho-tau (p-tau) pathology. In HIV disease, prior studies of these neuropathologic changes were relatively limited. Here, we characterized Aβ plaques and p-tau lesions by immunohistochemistry in relevant brain regions (prefrontal neocortex, putamen, basal-temporal neocortex, and hippocampus) of HIV-infected adults. We used multivariable logistic regression to predict regional Aβ plaque or p-tau pathology based on demographic factors, apolipoprotein E (APOE) genotypes, HIV disease-related factors, and regional gliosis. We used multiple linear regression to predict T-scores in neuropsychological domains based on regional Aβ plaque or p-tau pathology. We found that APOE ε4 alleles, older age, and higher plasma HIV-1 RNA predicted prefrontal Aβ plaques (odds ratio (OR) 5.306, 1.045, and 0.699, respectively, n = 168). Older age predicted putamen Aβ plaques (OR 1.064, n = 171). APOE ε4 alleles, hepatitis C virus seropositivity, and higher plasma HIV-1 RNA predicted hippocampus Aβ plaques (OR 6.779, 6.138, and 0.589, respectively, n = 56). The p-tau lesions were sparse in the vast majority of affected cases. Lifetime substance use disorder and higher plasma HIV-1 RNA predicted putamen p-tau lesions (OR 0.278 and 0.638, respectively, n = 67). Older age and gliosis predicted hippocampus p-tau lesions (OR 1.128 and 0.592, respectively, n = 59). Prefrontal Aβ plaques predicted lower speed of information processing (n = 159) and putamen Aβ plaques predicted lower levels of attention and working memory (n = 88). Regional p-tau lesions were not significantly predictive of any neuropsychological domains. In conclusion, Aβ plaque or p-tau pathology in different brain regions was predicted by different sets of biological factors. Aβ plaques in prefrontal neocortex and putamen predicted poorer functioning in cognitive domains relevant to these brain regions. The absence of significant impact of regional p-tau lesions on neuropsychological functioning might be explained by the subthreshold burden of p-tau lesions.
Introduction
Due to widespread implementation of highly active antiretroviral therapy (HAART), the life expectancy of HIV-infected persons has drastically increased (Teeraananchai et al. 2017) . The prevalence of older HIV-infected persons is increasing. For instance, in the USA, persons aged 50 years or older accounted for 48.2% of all HIV-infected people in 2016 and constituted 17% of new HIV diagnoses in 2017 (Centers for Disease Control and Prevention 2017). With increasing age, the general population is increasingly susceptible to the development of cerebral extracellular amyloid-β (Aβ) plaques and neuronal phospho-tau (p-tau) lesions (Braak et al. 2011) , putatively involved in the pathogenesis of Alzheimer's disease (Hyman et al. 2012) . Importantly, these neuropathologic changes may contribute to aging-related neuropsychological decline in certain functioning domains (Jicha et al. 2012; Price et al. 2009 ).
Based on large-scale non-selected general autopsy studies (Braak et al. 2011; Thal et al. 2015) , Aβ plaque pathology first appears in the cerebral neocortex of adults in their fourth decade of life and progresses with age to involve the allocortex, striatum, and other brain regions in a characteristic sequence. It is estimated that Aβ plaque pathology affects 75% of people by their tenth decade (Braak et al. 2011) . On the other hand, the cerebral involvement of neuronal p-tau pathology starts in the allocortex and expands into the basal-temporal and prefrontal neocortex (Braak et al. 2011) . Nonetheless, p-tau pathology can develop in some contexts other than natural brain aging and exhibit different patterns of regional progression, such as that p-tau pathology described in chronic traumatic encephalopathy (McKee et al. 2013) .
Compared with non-HIV control participants, HIVinfected adults showed evidence of accelerated brain aging in structural (Pfefferbaum et al. 2014 ) and functional (Ances et al. 2010 ) magnetic resonance imaging studies and in DNA methylation epigenetic analyses (Horvath and Levine 2015; Levine et al. 2016a ). Accordingly, HIV-infected persons may be vulnerable to the premature development of cerebral Aβ plaque or p-tau pathology. A number of autopsy studies of HIV-infected individuals described cerebral Aβ plaque or ptau pathology (Anthony et al. 2006; Esiri et al. 1998; Gelman and Schuenke 2004; Green et al. 2005; Izycka-Swieszewska et al. 2000; Rempel and Pulliam 2005; Smith et al. 2014; Soontornniyomkij et al. 2012a ). Nonetheless, these previous studies were relatively limited in terms of biological factors predicting these neuropathologic changes and the neuropsychological implications.
In the present study, we characterized Aβ plaques and ptau lesions in four brain regions (i.e., prefrontal neocortex, putamen, basal-temporal neocortex, and hippocampus), considered pertinent to both HIV disease (Wiley et al. 1998 ) and the regional progression of these neuropathologic changes (Braak et al. 2011; Thal et al. 2015) . We investigated what clinically relevant biological factors (i.e., demographic factors, apolipoprotein E (APOE) genotypes (Bennett et al. 2009; Polvikoski et al. 1995) , HIV disease-related factors, and regional gliosis) could predict regional Aβ plaque or ptau pathology. Moreover, we assessed whether regional Aβ plaque or p-tau pathology could predict functioning in individual neuropsychological domains.
Methods

Study cohort
We studied 285 autopsy HIV-infected adult cases that had paraffin-embedded tissue samples from at least one of middle frontal gyrus, putamen, and basal-temporal region/ hippocampus blocks available in the National NeuroAIDS Tissue Consortium (NNTC) in the USA (Request # R432 and # R458). In the basal-temporal region/hippocampus block, neuropathologic changes were assessed in two separate brain regions: basal-temporal neocortex and hippocampus. The University of California San Diego Human Research Protections Program approved the project. All study participants provided written informed consent to participate, and the written consent to autopsy was obtained. Our study included only participants whose races/ethnicities were Caucasian, African American, or Hispanic, because of the relatively small number of participants of other races/ethnicities. The biological factors, confounders, neuropathological outcomes, and neuropsychological domain T-scores are summarized in Table 1 . Of 285 cases studied, not every case had all brain tissue samples and biological data.
Using univariable logistic regression, we evaluated individually 10 biological factors considered clinically relevant to neuropathological outcomes studied (i.e., Aβ plaque and p-tau pathology) in the context of HIV disease: age at death, sex, race/ethnicity, presence of one or two APOE ε2 or ε4 alleles (Bennett et al. 2009; Polvikoski et al. 1995) , hepatitis C virus (HCV) seropositivity, lifetime substance use disorder (current or past substance abuse or dependence of any of alcohol, cannabis, cocaine, methamphetamine, and opiates, diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders), use of HAART regimens at the last clinical assessment (vs. use of non-HAART regimens, discontinuation of antiretroviral therapy (ART), or being ART-naive), plasma HIV-1 RNA load (log 10 copies/ml) at the last clinical assessment, presence of HIV encephalitis, and regional gliosis.
There might be NNTC site differences in biological factors (e.g., those related to geographical areas or social environs) for which could not be specifically accounted in our study. In addition, we could not exclude a possibility of certain interlaboratory preanalytical differences that were relevant to immunohistochemistry, including materials and equipment from different manufacturers. We, therefore, included the NNTC site difference, as well as the postmortem delay (> 12 h), as confounders in logistic regression models (Bao and Swaab 2018; Price et al. 2009 ).
Neuropsychological assessment
HIV-infected participants were evaluated with a multidomain neuropsychological test battery within 1 year prior to death. Seven domains of neuropsychological functioning were assessed: executive functions, speed of information processing, attention and working memory, learning, delayed recall, verbal fluency, and motor (Woods et al. 2004 ). Individual neuropsychological test T-scores were assigned using normative data correcting for age, sex, race/ethnicity, and education when indicated and possible (Woods et al. 2004) . The neuropsychological domain T-scores (with possible ranges of 19 to 80) were derived from averaging individual test T-scores in the same domains. Higher domain T-scores indicated higher levels of neuropsychological functioning.
Histopathology and APOE genotyping
Histopathologic diagnoses were made by site neuropathologists in the NNTC. HIV encephalitis was defined as multiple foci of microgliosis, multinucleated giant cells, and astrogliosis in the brain (Budka et al. 1991) . APOE genotypes (ε2, ε3, and ε4 alleles) were determined at the University of California Los Angeles Biological Samples Processing Core. The Autopure LS nucleic acid purification instrument was used to extract DNA from frozen occipital cortex tissue samples. Single nucleotide polymorphism genotyping (rs429358 and rs7412) was performed on the Sequenom MassARRAY iPLEX platform (Agena Bioscience, San Diego, CA, USA), as previously described (Levine et al. 2016b ). The presence of one or two APOE ε4 alleles was not statistically significantly different across the race/ethnicity groups (χ 2 = 2.383, df = 2, n = 254, p = 0.304, Pearson chi-square test). On the other hand, there was a difference in the frequency of participants with one or two APOE ε2 alleles across the race/ethnicity groups (χ 2 = 6.990, df = 2, n = 254, p = 0.030, Pearson chisquare test). In particular, the APOE ε2 allele was rare among Hispanic participants (Table 1) .
To assess the predictive effects of APOE ε4 and ε2 alleles on Aβ plaque or p-tau pathology, we first simultaneously tested for dominant main effects and an interaction effect between ε4 and ε2 alleles in order to allow the inclusion of participants carrying the APOE ε4/ε2 genotype. Symbolically, this model was represented as:
where I {ε4/ε4, ε4/ε3, ε4/ε2} = 1 if the APOE genotype was ε4/ε4, ε4/ε3, or ε4/ε2 and = 0 otherwise, and I {ε2/ε2, ε2/ε3, ε4/ε2} = 1 if the APOE genotype was ε2/ε2, ε2/ε3, or ε4/ε2 and = 0 otherwise. This three-parameter model represented our most general model for the effects of APOE and allowed for difference in effects from the referent genotype ε3/ε3 to be determined. When a more parsimonious model with fewer parameters was statistically supported, e.g., a model with only the dominant effect of APOE ε4 over both ε2 and ε3 could not be rejected (Logit(Y) = α + β ε4 I {ε4/ε4, ε4/ε3, ε4/ε2} ), we used the model with fewer parameters. The specific model used is specified in the footnotes of Tables 2 and 3 .
Immunohistochemistry
We conducted immunohistochemistry on 5-μm-thick tissue sections prepared from three paraffin-embedded formalinfixed brain blocks: middle frontal gyrus, putamen, and basal-temporal region/hippocampus. Primary antibodies used were directed against Aβ 17-24 (clone 4G8, SIG-39220, Covance, Princeton, NJ, USA; dilution 1:20,000), p-tau (clone AT8, MN1020, Pierce Biotechnology, Rockford, IL, USA; 1:1000), ionized calcium-binding adapter molecule-1 (Iba1, microglia/macrophage marker; 019-19741, Wako, Richmond, VA, USA; 1:1000), and glial fibrillary acidic protein (GFAP, astroglia marker; Z0334, Dako, Carpinteria, CA, USA; 1:1000). The immunohistochemical staining procedures were carried out with diaminobenzidine (DAB) as a chromogen, as previously described (Soontornniyomkij et al. 2012b (Soontornniyomkij et al. , 2016 . The Aβ and p-tau immuno-labeled tissue sections were counterstained with Mayer hematoxylin. Neocortex sections from an Alzheimer's disease brain (a gift from Dr. Eliezer Masliah, Departments of Pathology and Neurosciences, University of California San Diego) were used as the positive tissue controls for Aβ and p-tau immunohistochemistry in all staining batches.
Assessments of regional Aβ plaque and p-tau pathology
Aβ plaque pathology was designated as present when extracellular Aβ-immunoreactive plaques were observed, regardless of their type (Duyckaerts et al. 2009 ) or density. The density of Aβ plaques was graded as absent, focal, or widespread, as described previously (Soontornniyomkij et al. 2012a) . Neuronal p-tau pathology was designated as present when there were p-tau-immunoreactive neuropil threads, pretangle neuronal soma, neurofibrillary tangles, or their combinations (Duyckaerts et al. 2009; Soontornniyomkij et al. 2018) . The density of neuropil threads was graded as 0 (absent), 1 (barely present at × 100 magnification), 2 (easily noted at × 100 magnification), or 3 (notable with naked eye inspection), a scoring system adapted from a BrainNet Europe Consortium study (Alafuzoff et al. 2008 ), as previously described (Soontornniyomkij et al. 2018 ).
Assessments of regional gliosis
We regarded regional microgliosis (Ransohoff and Cardona 2010) and astrogliosis (Sofroniew and Vinters 2010) as summed neuropathologic indicators of inflammatory and reparative responses to neural injury accumulating in the course of HIV disease and its comorbidities. Immunohistochemistry for Iba1 showed resident microglia and perivascular macrophages, and that for GFAP showed diffusely distributed n/a n/a n/a n/a n/a MHBB < 0.001 (+), 268 n/a n/a n/a APOE apolipoprotein E, HCV hepatitis C virus, NNTC National NeuroAIDS Tissue Consortium, CNTN California NeuroAIDS Tissue Network, NNAB National Neurological AIDS Bank, TNRC Texas NeuroAIDS Research Center, MHBB Manhattan HIV Brain Bank, n/a not applicable a Univariable logistic regression analysis model. Each regional amyloid-β plaque or neuronal phospho-tau pathology was regressed on each biological factor or confounder. Denoted in italics are the four most significant biological factors or confounders by the univariable analyses that have p values of less than 0.10 (with direct (+) or inverse (−) association) for each regional neuropathological outcome. These factors and confounders were subsequently included in the multivariable logistic regression analysis model and the final model was selected using a backward stepwise approach ( otherwise. We found that the best fitting model had a dominant effect of ε2 over both ε3 and ε4 such that individuals with APOE genotypes ε2/ε2, ε2/ε3, or ε4/ε2 were predicted to be at decreased risk relative to individuals with APOE genotypes ε4/ε4, ε4/ε3, or ε3/ε3 albeit these risks were not statistically significant n/a n/a TNRC n/a n/a n/a n/a MHBB n/a n/a n/a n/a n/a n/a n/a ε2 n/a n/a n/a n/a HCV seropositivity n/a n/a n/a n/a n/a n/a n/a n/a OR odds ratio, CI confidence interval, APOE apolipoprotein E, HCV hepatitis C virus, NNTC National NeuroAIDS Tissue Consortium, CNTN California NeuroAIDS Tissue Network, NNAB National Neurological AIDS Bank, TNRC Texas NeuroAIDS Research Center, MHBB Manhattan HIV Brain Bank, n/a not applicable astroglia of variable density, as previously described (Soontornniyomkij et al. 2016 ).
Quantifications of Iba1 and GFAP immunoreactivity on the DAB tissue slides were performed by using a microscope slide scanner (Aperio ScanScope GL, Leica Biosystems, Buffalo Grove, IL, USA), Aperio ImageScope software, and Image-Pro Analyzer software (Version 6.3, Media Cybernetics, Bethesda, MD, USA), as described previously (Soontornniyomkij et al. 2018 ). The DAB intensity was quantified within each area of interest (i.e., the prefrontal neocortex (layers II-VI), basal-temporal neocortex (layers II-VI), putamen, and hippocampal CA1). The DAB intensity per unit area (i.e., DAB density) was calculated, as described previously (Soontornniyomkij et al. 2012b) . To adjust for the betweenbatch variation, one brain section from the same positive tissue control block was included in each immunostaining batch. The control DAB density value (in a specified area) was used to normalize all the DAB density values of studied cases in the same batch, generating the immunoreactivity density values (continuous variables).
In the prefrontal neocortex, putamen, basal-temporal neocortex, and hippocampal CA1, the immunoreactivity density values of Iba1 and GFAP showed direct correlations (Spearman's rho 0.293, 0.422, 0.482, and 0.559; n = 268, 171, 71, and 71, respectively; p < 0.001 all). Therefore, in each of the brain regions, we transformed each of the Iba1 and GFAP immunoreactivity density values into a score of 1, 2, or 3 by tertile cutoffs, and generated a gliosis score (composite score of microgliosis and astrogliosis: 2, 3, 4, 5, or 6) by summing Iba1 and GFAP scores.
Statistical analysis
We performed univariable logistic regression analyses regressing each regional Aβ plaque or p-tau pathology against each of the biological factors and confounders (Table 2) . To reduce bias in small sample sizes and deal with the issue of quasi-complete separation, we used the Firth penalized maximum likelihood method (with profile penalized log likelihood confidence intervals [CI]), instead of standard maximum likelihood estimation (Allison 2012) . Because of the small sample sizes, we needed to limit the number of predictors to be included in the subsequent multivariable logistic regression even when using Firth penalized logistic regression. Thus, we chose the four most significant biological factors or confounders having p < 0.10 to be subsequently included in the multivariable Firth penalized logistic regression model of prediction. We then used a backward stepwise model selection approach to determine the final model (Table 3) : each regional Aβ plaque or p-tau pathology was regressed on those biological factors and confounders. We presented the effect sizes as odds ratios (OR) and included their 95% CI. The paraffin-embedded tissue samples from putamen and basal-temporal region/hippocampus blocks were not available from TNRC or MHBB
We conducted multiple linear regression analyses to predict each neuropsychological domain T-score based on regional Aβ plaque or p-tau pathology, controlling for age, sex, and race/ethnicity (Table 4 ). In the process of assigning individual neuropsychological test T-scores, the statistical correction for potential covariates might not be uniformly applied to all neuropsychological tests and participants. We therefore uniformly included age, sex, and race/ethnicity in multiple linear regression models for predicting each neuropsychological domain T-score. General linear model (univariate): Each neuropsychological domain T-score was regressed on each regional Aβ plaque or p-tau pathology, along with age, sex, and race/ethnicity. The unstandardized coefficient (B) measured the effect size.
Of 285 cases studied, not every case had all brain tissue samples and biological data ( Table 1 ). The statistical analyses were performed on available cases, with pairwise exclusion. Two-sided p values were considered statistically significant if p < 0.05. The p values reported in the present study were not adjusted for the family-wise type I error in multiple comparisons. The statistical analyses were performed using R (The R Project for Statistical Computing) Version 3.5.2 and IBM SPSS Statistics Version 25.
Results
Aβ plaque pathology
The vast majority of Aβ plaques found in four brain regions examined were of diffuse type (Fig. 1a-d) , as previously described (Soontornniyomkij et al. 2012a ). Aβ plaque pathology (Table 1) was present in 79 (focal in 59 and widespread in 20) of 268 cases (29.5%) in the prefrontal neocortex, 24 (focal in 22 and widespread in 2) of 171 cases (14.0%) in the putamen, 16 (focal in 6 and widespread in 10) of 71 cases (22.5%) in the basal-temporal neocortex, and 22 (focal in 18 and widespread in 4) of 71 cases (31.0%) in the hippocampus. The youngest case having focal Aβ plaque pathology in the prefrontal neocortex was 30 years old at death, in the putamen 33 years, in the basal-temporal neocortex 34 years, and in the hippocampus 33 years. The youngest case having widespread Aβ plaque pathology in the prefrontal neocortex was 44 years old at death, in the putamen 57 years, in the basal-temporal neocortex 46 years, and in the hippocampus 49 years.
The confounders, postmortem delay and NNTC site difference, were significantly associated only with putamen Aβ plaque pathology in the univariable logistic regression analyses (Table 2 ) and therefore included only in that multivariable (Table 2) , and so the multivariable analysis was not conducted.
Neuronal p-tau pathology
Representative features of neuronal p-tau pathology in four brain regions examined are shown in Fig. 1e -h. In the prefrontal neocortex, p-tau pathology (Table 1) was present in 119 of 268 cases (44.4%). Of these 119 cases, 112 cases had neuropil threads of grade 1 density, four cases with grade 2, and one case with grade 3; the remaining two cases having pretangle or tangle-bearing neuronal soma without neuropil threads. In the putamen, p-tau pathology was present in 37 of 122 cases (30.3%). Of these 37 cases, 34 cases had neuropil threads of grade 1 density and one case with grade 2; the remaining two cases having pretangle or tangle-bearing neuronal soma without neuropil threads. In the basal-temporal neocortex, p-tau pathology was present in 45 of 71 cases (63.4%). Of these 45 cases, 36 cases had neuropil threads of grade 1 density, eight cases with grade 2, and the remaining case with grade 3. In the hippocampus, p-tau pathology was present in 40 of 71 cases (56.3%). Of these 40 cases, 35 cases had neuropil threads of grade 1 density and three cases with grade 2; the remaining two cases having pretangle or tanglebearing neuronal soma without neuropil threads. The confounder NNTC site difference was significantly associated in the univariable logistic regression analyses of prefrontal, basal-temporal, and hippocampus p-tau pathology (Table 2 ) and so included in these multivariable analyses. In multivariable logistic regression analyses (Table 3) , lifetime substance use disorder and higher plasma HIV-1 RNA load predicted lower likelihood of putamen p-tau pathology (OR 0.278 [95% CI 0.079, 0.979], p = 0.032, and OR 0.638 [95% CI 0.436, 0.934] , p = 0.013, respectively, n = 67). Increasing age predicted higher likelihood of hippocampus p-tau pathology (OR 1.128 [95% CI 1.040, 1.224], p < 0.001), whereas gliosis score predicted lower likelihood (OR 0.592 [95% CI 0.365, 0.961] , p = 0.024, n = 59). Gliosis score, the only biological factor significantly associated with lower likelihood of prefrontal p-tau pathology in the univariable analysis, showed Immunohistochemistry for phospho-tau shows neuropil threads (arrowheads and insets) and neurofibrillary tangle-bearing neurons (arrows and insets) in the prefrontal neocortex (e) of a 44-year-old African American man, the putamen (f) of a 44-year-old Caucasian man, and the basal-temporal neocortex (g) and hippocampus (h) of a 66-year-old Caucasian man (the same case as in a-d). Scale bars, 300 μm for amyloid-β plaque and 100 μm for phospho-tau pathology no significant association when controlling for NNTC site difference (n = 268).
Although using the Firth penalized maximum likelihood method improved the stability of logistic regression models over standard maximum likelihood estimation (data not shown), the effect size of HAART use (OR 7.740 [95% CI 0.902, 66 .405], p = 0.028, n = 59) on hippocampus p-tau pathology (Table 3 ) might be imprecisely estimated. The instability was most likely due to the small sample size. Similarly, the effect sizes of African American race/ethnicity (OR 11.527 [95% CI 1.145, 116 .01], p = 0.018) and HCV seropositivity (OR 12.363 [95% CI 1.749, 87 .381], p = 0.002) on basaltemporal p-tau pathology, controlling for NNTC site difference, might be considered biased and imprecise due to the small sample size (n = 61).
Neuropsychological functioning
For neuropsychological functioning (Table 4) , prefrontal Aβ plaque pathology predicted lower speed of information processing (B − 3.928, p = 0.032, n = 159) and putamen Aβ plaque pathology predicted lower levels of attention and working memory (B − 6.269, p = 0.020, n = 88), when controlling for age, sex, and race/ethnicity. Regional p-tau pathology was not significantly predictive of any neuropsychological functioning domains.
Discussion
In the present study of HIV-infected adults, the vast majority of Aβ plaques found in four brain regions examined were of diffuse type, consistent with the early stages of Aβ plaque development (Duyckaerts et al. 2009 ). The occurrence of Aβ plaque pathology in the four brain regions was predicted by different sets of biological factors. For instance, the presence of APOE ε4 alleles was associated with Aβ plaque pathology in the prefrontal neocortex and hippocampus, but not in the putamen or basal-temporal neocortex. The APOE isoforms differentially regulate Aβ clearance and aggregation probably by multiple pathways such as binding to lipoprotein receptors involved in Aβ clearance (Verghese et al. 2013; Zhao et al. 2018 ). There may be brain region-dependent factors that can modulate Aβ metabolism, such as the microvascular architecture and function regulating Aβ clearance via vascular basement membrane pathways (Morris et al. 2016) .
With regard to neuropsychological functioning, we found that Aβ plaque pathology in the prefrontal neocortex and putamen was associated with poorer functioning in speed of information processing and attention/working memory, respectively, cognitive domains relevant to these brain regions (Arsalidou et al. 2013; Dux et al. 2009 ). Our findings in HIVinfected adults agree with the observation that with age the general population is increasingly susceptible to diffuse Aβ plaque pathology, which may contribute to aging-related neuropsychological decline in certain functioning domains (Jicha et al. 2012; Price et al. 2009 ).
Among the four brain regions examined, we found that older age was associated with neuronal p-tau pathology only in the hippocampus. This finding is in agreement with the natural age-dependent sequence of cerebral regional progression of p-tau pathology, starting in the allocortex (Braak et al. 2011 ). It was difficult to interpret the effect of HAART use on hippocampus p-tau pathology because the OR 95% CI value was wide (Table 3) , indicating the instability of the logistic regression model, which was most likely due to the small sample size (de Irala et al. 1997) . The same scenario could also apply to the interpretation of the effects of race/ethnicity and HCV seropositivity on basal-temporal p-tau pathology (with wide OR 95% CI values); however, our findings are suggestive of the predictive effects and further studies using larger sample sizes are warranted.
In our study, although neuronal p-tau pathology was found in approximately one third to two thirds of cases, depending on brain regions, these p-tau lesions were sparse (i.e., neuropil threads of grade 1 density) in the vast majority of affected cases. We found that regional p-tau pathology was not significantly predictive of any neuropsychological functioning domains. Considering the extent and density of p-tau lesions characteristically found in symptomatic cases of sporadic late-onset Alzheimer's disease (Duyckaerts et al. 2009; Hyman et al. 2012) , the absence of significant impact of regional p-tau pathology on neuropsychological functioning in our study might be explained by the subthreshold burden of ptau lesions, as well as the small sample sizes especially regarding the basal-temporal neocortex and hippocampus regions (Jicha et al. 2012 ).
Our present study had limitations inherent to research work using autopsy human specimens. HIV-infected individuals were recruited into the NNTC because they were at known risk of death. Not every study case had all brain tissue samples and biological data of interest (Table 1) , which led to limited statistical power in multivariable logistic regression analyses. For example, the basal-temporal region/hippocampus block was available in only approximately one fourth of cases that had the middle frontal gyrus block available. The present study did not assess other neuropathologic changes that might also play a role in neuropsychological decline, including cerebrovascular disease, neocortical alpha-synucleinopathy, and TAR DNA binding protein (TDP-43) proteinopathy (Hyman et al. 2012; Jicha et al. 2012) . Further studies on these neurodegenerative changes are warranted.
In conclusion, our study showed that occurrence of Aβ plaque or p-tau pathology in different brain regions of HIVinfected adults was associated with different sets of biological factors. Aβ plaque pathology in the prefrontal neocortex and putamen was associated with poorer functioning in cognitive domains relevant to these brain regions. The absence of significant impact of regional p-tau pathology on neuropsychological functioning might be explained by the subthreshold burden of p-tau lesions or insufficient statistical power. Systematic multi-region assessments of a broad range of neurodegenerative changes in large HIV cohorts may expand our understanding of the development of aging-related neuropsychological decline or neurodegenerative disorders in their early stages.
